X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs CADILA HEALTHCARE - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD CADILA HEALTHCARE WYETH LTD/
CADILA HEALTHCARE
 
P/E (TTM) x 27.7 18.9 146.3% View Chart
P/BV x 5.3 4.3 124.6% View Chart
Dividend Yield % 1.3 1.0 133.5%  

Financials

 WYETH LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    WYETH LTD
Mar-13
CADILA HEALTHCARE
Mar-18
WYETH LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,044558 187.2%   
Low Rs818362 226.3%   
Sales per share (Unadj.) Rs298.6116.3 256.7%  
Earnings per share (Unadj.) Rs57.217.9 320.4%  
Cash flow per share (Unadj.) Rs58.423.1 252.5%  
Dividends per share (Unadj.) Rs17.003.50 485.7%  
Dividend yield (eoy) %1.80.8 239.8%  
Book value per share (Unadj.) Rs249.585.4 292.1%  
Shares outstanding (eoy) m22.721,023.74 2.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.0 78.9%   
Avg P/E ratio x16.325.7 63.2%  
P/CF ratio (eoy) x15.919.9 80.2%  
Price / Book Value ratio x3.75.4 69.3%  
Dividend payout %29.719.6 151.6%   
Avg Mkt Cap Rs m21,157470,664 4.5%   
No. of employees `0000.511.8 4.2%   
Total wages/salary Rs m40018,545 2.2%   
Avg. sales/employee Rs Th13,787.410,072.7 136.9%   
Avg. wages/employee Rs Th813.01,569.1 51.8%   
Avg. net profit/employee Rs Th2,643.31,547.7 170.8%   
INCOME DATA
Net Sales Rs m6,783119,049 5.7%  
Other income Rs m3531,132 31.1%   
Total revenues Rs m7,136120,181 5.9%   
Gross profit Rs m1,61728,475 5.7%  
Depreciation Rs m275,388 0.5%   
Interest Rs m6911 0.6%   
Profit before tax Rs m1,93823,308 8.3%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6325,644 11.2%   
Profit after tax Rs m1,30118,292 7.1%  
Gross profit margin %23.823.9 99.7%  
Effective tax rate %32.624.2 134.7%   
Net profit margin %19.215.4 124.8%  
BALANCE SHEET DATA
Current assets Rs m6,98482,005 8.5%   
Current liabilities Rs m2,05660,720 3.4%   
Net working cap to sales %72.617.9 406.3%  
Current ratio x3.41.4 251.5%  
Inventory Days Days9973 135.7%  
Debtors Days Days2498 24.4%  
Net fixed assets Rs m24483,703 0.3%   
Share capital Rs m2271,024 22.2%   
"Free" reserves Rs m5,44186,421 6.3%   
Net worth Rs m5,66887,445 6.5%   
Long term debt Rs m2525,551 0.1%   
Total assets Rs m7,901180,653 4.4%  
Interest coverage x353.326.6 1,329.0%   
Debt to equity ratio x00.3 1.5%  
Sales to assets ratio x0.90.7 130.3%   
Return on assets %16.510.6 155.5%  
Return on equity %22.920.9 109.7%  
Return on capital %34.022.0 154.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1542,683 0.0%   
Fx outflow Rs m2,67711,242 23.8%   
Net fx Rs m-2,66231,441 -8.5%   
CASH FLOW
From Operations Rs m9239,193 10.0%  
From Investments Rs m317-9,737 -3.3%  
From Financial Activity Rs m-481515 -93.4%  
Net Cashflow Rs m759-29 -2,617.6%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 8.3 136.1%  
FIIs % 7.2 5.9 122.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 11.0 276.4%  
Shareholders   21,978 44,069 49.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; Energy & PSU Stocks Outperform(12:30 pm)

Stock markets in India are trading range-bound in the afternoon session. Among the sectoral indices, IT stocks and healthcare stocks are witnessing maximum selling pressure.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WYETH LTD WITH

MARKET STATS